Internal FDA emails reveal how price, Sanders’ pressure played a role in competitor’s approval, Catalyst claims

A series of partially redacted internal emails from the FDA, released as part of a lawsuit related to competing treatments for the rare disorder Lambert-Eaton Myasthenic Syndrome (LEMS), attempt to show how price and Sen. Bernie Sanders’s (D-VT) pressure played a role in FDA’s approval of a competitor.